Compare HNVR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | UNCY |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 145.3M |
| IPO Year | 2022 | 2021 |
| Metric | HNVR | UNCY |
|---|---|---|
| Price | $23.23 | $8.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $24.50 | ★ $25.67 |
| AVG Volume (30 Days) | 9.3K | ★ 526.3K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | $582.86 |
| P/E Ratio | $23.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $0.47 |
| 52 Week High | $24.49 | $8.34 |
| Indicator | HNVR | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 55.80 | 63.04 |
| Support Level | $22.93 | $5.95 |
| Resistance Level | $24.38 | N/A |
| Average True Range (ATR) | 0.42 | 0.39 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 41.86 | 71.87 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.